Lilly locks in 5-program R&D pact with China’s Haisco worth up to $3B, but targets unclear Read more
Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome Read more
ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34% Read more
